# LSP

> LSP is a VC fund backing Health Care, Medical Device and Therapeutics. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 3
- Last investment: Jun 2020
- Lead investor: 67%
- Last updated: Aug 2026
- Website: http://leansigmaplus.com

LSP is a defense & space company that offers strategy consulting services.

## Contacts

5 contacts available for LSP. Shizune tracks 1 team members at LSP. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/lsp?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 100% |
| Medical Device | 3 | 100% |
| Therapeutics | 2 | 67% |
| Biotechnology | 1 | 33% |
| Manufacturing | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 33% |
| Series C | 1 | 33% |
| Series D | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 2 | 67% |
| Switzerland | 1 | 33% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Lee Shapiro | Founder | 0 | https://shizune.co/investors/profile/lee-shapiro-6c19 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| etherna immunotherapies | eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable andsafer enhancement of the patient’s immune system than any other similar approach investigated until now. | $38.3M | Series B | Jun 16, 2020 |  |
| Xeltis | A clinical-stage medical device company, Xeltis has developed the most advanced polymer-based restorative devices for cardiovascular treatment. Xeltis’ restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and for coronary artery bypass graft (CABG) surgery and pulmonary heart valves, for whichclinical trials are ongoing. Xeltis was formed through the merger of two Dutch/Swiss university spin-offs. It currently has operations in The Netherlands and in the USA. Xeltis’ investors include venture capital funds EQT Life Sciences, Kurma Partners, VI Partners and Ysios Capital as well as a number of private investors. In 2021, Xeltis secured a €15 million financing from the European Investment Bank and a €15 million funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. | $11.5M | Series D | Sep 06, 2019 |  |
| iSTAR Medical | iSTAR Medical SA was created in 2010 as a spinout of Healionics Corporation with support from Belgium's Region Wallonne government. In 2011, iSTAR expanded to its new eco-friendly R&D and Manufacturing facility in CREALYS Scientific Park near Namur, Belgium.By 2012, iSTAR received ISO 13485 and ISO 9001 Quality SystemsCertifications and achieved CE Mark approval of its first device - STARflo™ Glaucoma Implant. | $43.9M | Series C | Sep 05, 2019 |  |

3 of 3 investments shown.

## Co-investors
- [BNP Paribas Private Equity](https://shizune.co/investors/profile/bnp-paribas-private-equity) — VC Fund, 2 deals together
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 1 deal together
- [Capricorn Partners](https://shizune.co/investors/profile/capricorn-partners) — VC Fund, 1 deal together
- [China Grand Pharmaceutical and Healthcare Holdings](https://shizune.co/investors/profile/china-grand-pharmaceutical-and-healthcare-holdings) — VC Fund, 1 deal together
- [Earlybird Venture Capital](https://shizune.co/investors/profile/earlybird-venture-capital) — VC Fund, 1 deal together
- [Fund+](https://shizune.co/investors/profile/fund) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does LSP invest in?

LSP invests primarily in Health Care, Medical Device and Therapeutics startups, most often at Series B and Series C stage. Most of the 3 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact LSP?

Public channels for LSP include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at LSP?

The team at LSP includes Lee Shapiro (Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co